Although line-probe assays (LPAs) are promising, little research has been conducted to elucidate the true nature of indeterminate LPA results or assess the ability of these assays to perform on a wide range of clinical samples. O B J E C T I V E : To evaluate the performance of the commercially available GenoType w MTBDRplus LPA against conventional BACTECe MGITe 960 culture and drug susceptibility testing (DST) among 308 pulmonary tuberculosis (PTB) and 32 extra-pulmonary TB samples. R E S U LT S : Invalid LPA results (defined as those with a missing Mycobacterium tuberculosis identification band) were obtained for 18 PTB samples, which were excluded from further analysis. The sensitivity and specificity of the MTBDRplus assay for multidrugresistant TB, based upon the results obtained for the remaining 322 samples, was respectively 95.2% and 95.1%. Of 290 PTB samples, 40 (13.7%) were indeterminate on LPA (defined as the absence of both wild-type and corresponding mutation bands) for isoniazid (INH) and/or rifampicin (RMP), and were further evaluated by pyrosequencing (PSQ). Contrary to standard LPA interpretation, INH and RMP susceptibility were confirmed by both DST and PSQ in respectively 7.5% (3/40) and 27.5% (11/40) of indeterminate samples. C O N C L U S I O N : PSQ was found to be a valuable and rapid technique to resolve discrepancies in LPA test results that were not interpretable. K E Y W O R D S : tuberculosis; drug resistance; pyrosequencing; heteroresistance; indeterminate TUBERCULOSIS (TB) remains one of the world's deadliest communicable diseases. The recent increase in drug-resistant strains as a result of the ineffective treatment and increased direct transmission of resistance presents an important dilemma for global TB control efforts. 1 The detection of resistance is often delayed when using conventional phenotypic drug susceptibility testing (DST) methods due to the slow growth of Mycobacterium tuberculosis in liquid culture. Conventional growth-based diagnostic methods require approximately 4 weeks to generate results. 2 During this time, patients may be taking medications that are completely ineffective, and risk directly transmitting resistant disease to others. There is therefore an urgent need for rapid diagnostic tests for drug-resistant TB strains.
B A C K G R O U N D :
Although line-probe assays (LPAs) are promising, little research has been conducted to elucidate the true nature of indeterminate LPA results or assess the ability of these assays to perform on a wide range of clinical samples. O B J E C T I V E : To evaluate the performance of the commercially available GenoType w MTBDRplus LPA against conventional BACTECe MGITe 960 culture and drug susceptibility testing (DST) among 308 pulmonary tuberculosis (PTB) and 32 extra-pulmonary TB samples. R E S U LT S : Invalid LPA results (defined as those with a missing Mycobacterium tuberculosis identification band) were obtained for 18 PTB samples, which were excluded from further analysis. The sensitivity and specificity of the MTBDRplus assay for multidrugresistant TB, based upon the results obtained for the remaining 322 samples, was respectively 95.2% and 95.1%. Of 290 PTB samples, 40 (13.7%) were indeterminate on LPA (defined as the absence of both wild-type and corresponding mutation bands) for isoniazid (INH) and/or rifampicin (RMP), and were further evaluated by pyrosequencing (PSQ). Contrary to standard LPA interpretation, INH and RMP susceptibility were confirmed by both DST and PSQ in respectively 7.5% (3/40) and 27.5% (11/40) of indeterminate samples. C O N C L U S I O N : PSQ was found to be a valuable and rapid technique to resolve discrepancies in LPA test results that were not interpretable. K E Y W O R D S : tuberculosis; drug resistance; pyrosequencing; heteroresistance; indeterminate TUBERCULOSIS (TB) remains one of the world's deadliest communicable diseases. The recent increase in drug-resistant strains as a result of the ineffective treatment and increased direct transmission of resistance presents an important dilemma for global TB control efforts. 1 The detection of resistance is often delayed when using conventional phenotypic drug susceptibility testing (DST) methods due to the slow growth of Mycobacterium tuberculosis in liquid culture. Conventional growth-based diagnostic methods require approximately 4 weeks to generate results. 2 During this time, patients may be taking medications that are completely ineffective, and risk directly transmitting resistant disease to others. There is therefore an urgent need for rapid diagnostic tests for drug-resistant TB strains.
M. tuberculosis acquires drug resistance through the accumulation of resistance-associated mutations in specific genes. 2, 3 The World Health Organization (WHO) has recently approved a commercially available line-probe assay (LPA), the GenoType w MTBDRplus assay (Hain Lifescience, Nehren, Germany), which detects drug resistance based on the presence or absence of these specific resistanceassociated mutations. The diagnostic performance of the MTBDRplus assay is based on the amplification and genetic analysis of those gene regions known to harbor resistance-associated mutations, as determined by reverse hybridization to wild-type (wt) and mutated sequences. The assay detects the presence of M. tuberculosis as well as the most common genetic mutations conferring resistance to rifampicin (RMP) (mutations within the rpoB gene) and isoniazid (INH) (mutations within the katG gene and the inhA promoter), 4, 5 and its diagnostic performance has been well evaluated in pulmonary samples. 4 In the present study, the MTBDRplus diagnostic LPA was thoroughly evaluated for its ability to detect multidrug-resistant TB (MDR-TB) in pulmonary (PTB) and extra-pulmonary (EPTB) samples as compared to standard DST methods. Any discrepancies were further evaluated at the molecular level using pyrosequencing (PSQ), a real time sequencing method, to ascertain the true nature of indeterminate and discrepant test results.
MATERIALS AND METHODS

Setting
The study was performed at the P D Hinduja National Hospital and Medical Research Centre, Mumbai, India, from August 2011 to May 2013. The Mycobacteriology Laboratory at the Hinduja Hospital is accredited by the College of American Pathologists (CAP), the National Accreditation Board for Testing and Calibration Laboratories (NABL), and the Central TB Division, Government of India (CTD, GOI), for the performance of liquid culture and DST.
Study design and ethics statement
This single site, cross-sectional study was conducted to determine the diagnostic performance of the MTBDRplus assay in PTB and EPTB samples in comparison with conventional methodologies. Indeterminate results were further evaluated using pyrosequencing.
The study was approved by the Institutional Review Board of P D Hinduja National Hospital and Medical Research Centre (National Health and Education Society), Mumbai, India. The need for informed consent was waived, as the study was performed on existing sediments identified only by laboratory-generated numbers, with no traceability back to patients. All patient details remained confidential.
Sample collection
A total of 340 previously collected consecutive samples were used for the study. Both phenotypic and genotypic testing was conducted on 308 PTB samples (sputum) and 32 EPTB samples (pus, body fluid, biopsy, tissue, etc.).
Ziehl-Neelsen staining
All collected samples were graded according to WHO-recommended criteria. EPTB samples selected for the study were all smear-positive, as recommended for the MTBDRplus assay. 6 Sample processing All samples were processed using the N-acetyl-Lcysteine-sodium hydroxide method, as described previously. 7 Final sediments were resuspended in 2 ml phosphate buffered saline (PBS) (pH ¼ 7.4); 500 ll of this suspension was inoculated into a 7 ml MGIT tube and 500 ll was inoculated onto solid media (Löwenstein-Jensen). The remaining sediment was transferred to 1.5 ml screw cap tubes for further genotypic analysis. Sediments were stored at À808C when not in use.
Drug susceptibility testing
Positive liquid MGIT 960 cultures were subjected to further phenotypic DST. The drug concentrations used to determine RMP and INH susceptibility were respectively 1 lg/ml and 0.1 lg/ml. 8 Genotypic MTBDRplus assay DNA was extracted from 500 ll of each decontaminated patient sediment sample. All DNA samples were stored at À808C when not in use. The MTBDRplus assay was performed on each sample according to the manufacturer's instructions. 9 The assay contains six control probes: a conjugate control, an amplification control, an M. tuberculosis complex control, and rpoB, katG and inhA amplification controls. For the detection of INH and RMP resistance, the assay strip contains 21 mutation and wt probes: eight rpoB wt probes (covering codons 505 to 533); D516V, D526Y, H526D, and S531L, the four rpoB mutant probes; a katG codon 315 wt probe; two katG codon 315 mutant probes with AGC-ACC and AGC-ACA mutations; two inhA wt probes covering positions À15 and À16 of the gene regulatory region; and four inhA mutant probes with mutations CT at position À15, AG at position À16, TC at position À8, and TA at position À8. A detailed test flow chart for this study is given in Figure  1 . Assay results were considered invalid if the control probes were absent, and non-interpretable (NI) or indeterminate if the gene loci probe for both the wt and mutation probes being assessed was absent. The MTBDRplus assay was not repeated if the results were NI or indeterminate.
Pyrosequencing Pyrosequencing (PSQ) was performed on all samples found to be NI on MTBDRplus. The same extracted DNA sample as used for the LPA was used for PSQ. The PSQ assay used in this study involved three essential parts: amplification of gene fragments using polymerase chain reaction, capture of biotinylated single-stranded DNA on streptavidin sepharose beads, and sequencing by a commercially available modified PSQ platform. 10 Our PSQ assay included eight subassays: one for the identification of M. tuberculosis and seven for the detection of drug resistance mutations. For the determination of INH resistance, the assay sequences three loci: katG codons 312-316, the inhA promoter from À4 to À20, and the ahpC promoter from À4 to À23. Mutations in the ahpC promoter are believed to be compensatory to mutations in katG, which cause deficient catalase activities, and are indirectly associated with INH resistance. 11, 12 The molecular target included in the PSQ assay for the determination of RMP resistance is the RMP resistance-determining region of the rpoB gene (codons 507-533).
Statistical analysis
Diagnostic tests were evaluated according to STARD (Standards for Reporting Studies of Diagnostic Accuracy) recommendations. 13 Sensitivity and specificity were calculated by comparing phenotypic and molecular test results using Meta-DiSc software (Unit of Clinical Biostatistics, Ramón y Cajal Hospital, Madrid, Spain).
RESULTS
Concordance between LPA and DST results
A total of 322 samples were analyzed using the GenoType MTBDRplus assay and phenotypic DST, after excluding 18 samples with an undetected M. tuberculosis band on molecular testing. The average turnaround time for LPA within the context of our study was 2-3 days (data not shown). Of the 322 samples available for analysis, 290 were PTB and 32 were EPTB. According to the phenotypic DST results, 65% (211/322) of these were MDR-TB and 22.3% were susceptible to both RMP and INH. Phenotypic monoresistance to RMP and monoresistance to INH was observed in respectively 2.6% (8/322) and 10% (32/322) of the samples.
After excluding three samples with an undetected M. tuberculosis band, as above, the genotypic LPA assay found 40 samples to be NI, showing the absence of both wt and mutation probes for INH and/or RMP resistance detection (Table 1 ). LPA data were thus available for both RMP and INH in 282 samples (Table 2) . Of the total 322 samples evaluated using LPA, 59.2% (180/282) were confirmed to be MDR-TB and 27.6% (78/282) were found to be susceptible to both RMP and INH (Figures 2 and 3) . Monoresistance to RMP or INH was found in respectively 1.7% (5/282) and 6.7% (19/282) of samples with interpretable genetic data for both drug compounds. Table 2) .
Detection of mutations associated with drug resistance rpoB Mutant 3 (S531L) was the predominant mutation found in PTB (n ¼ 132) and EPTB (n ¼ 18) among the 172 RMP-resistant samples evaluated using LPA (Table 3) . For the 200 INH-resistant samples evaluated, katG Mutant 1 (315 AGC-ACC) was the predominant mutation identified among both PTB (n ¼ 153) and EPTB (n ¼ 18) samples (Table 4) .
DISCUSSION
The present study investigated the full performance of the GenoType MTBDRplus assay, assessing both interpretable and non-interpretable results for a range of PTB and EPTB samples. The sensitivity of the assay was found to be suboptimal in the smear-negative, culture-positive sputum samples and smear-positive EPTB samples evaluated. The sensitivity of LPA for MDR-TB was 95.29%; the specificity was 95.16%. The sensitivity for the detection of INH resistance was 89.29%, with a specificity of 95.95%. However, the MTBDRplus assay failed to detect 8.05% of INHresistant strains. The sensitivity for the detection of RMP resistance in our study was 91.98%, with a specificity of 95.79%; however, the assay failed to detect 5.31% of RMP-resistant strains. The S531L mutation in the rpoB gene was the most frequently occurring mutation among RMP-resistant strains (n ¼ 162), as observed in previous studies. [14] [15] [16] For determination of INH resistance, the S315T mutations in the katG gene were by far the most common found in our study (n ¼ 196). Recent studies have found the MTBDRplus assay to be an effective and feasible diagnostic tool for MDR-TB screening in endemic regions. 12, [17] [18] [19] [20] While the sensitivity of the molecular diagnostic test for the detection of INH resistance in our study was slightly lower than that for RMP and MDR-TB detection (compared to conventional methods), it was analogous to that of previously reported studies. 12, 20, 21 The slightly lower sensitivity of the MTBDRplus test for INH than conventional methods is likely due to the presence of genetic mutations conferring INH resistance that are located outside the katG and inhA promoter gene regions included in the LPA. 4, [22] [23] [24] In the present study, we did not identify any ahpC promoter mutations using PSQ, but other gene regions have been implicated in conferring resistance to INH that were not included in the assay, such as kasA. 4 An alternative explanation for the persistence of discordant results may be the presence of mixed populations of bacteria, consisting of both susceptible and resistant strains, and heteroresistance. 8, 25, 26 In the present study, 6.2% (18/290) of samples were considered heteroresistant on LPA and phenotypically resistant on MGIT DST. PSQ confirmed these samples to be genotypically resistant, indicating that observed discrepancies were likely due to signal overdevelopment during LPA, rather than mixed infection. As the MTBDRplus assay is currently only recommended for smear-positive samples because of its poor limit of detection for M. tuberculosis, the detection of heteroresistance is unlikely.
Indeterminate LPA results have been previously reported to be related to the smear and culture status of the evaluated samples, and generally occur in 1.4-19.2% of samples, depending on sample type (EPTB vs. PTB), 4 with uninterpretable readings only occurring in 6% of smear-positive sputum samples upon test repeat. 20 Our study found 12.4% of results to be NI without repeating the test. According to the manufacturer's instructions for reporting LPA results, samples demonstrating the absence of wt and corresponding mutation bands (NI/indeterminate results) are to be reported as resistant. Although this interpretation proved accurate for the majority of the INH NI and RMP NI results in our study, other LPA indeterminate results from this study were not as easily resolved, highlighting an important limitation of MTBDRplus. 27, 28 In the present study, NI results proved susceptible on DST and PSQ in a notable 7.5% (3/40) and 27.5% (11/40) of INH NI and RMP NI samples, respectively. Although the molecular basis of these discordant LPA results has not been fully elucidated, we can speculate as to the mechanisms behind test discordance. The occurrence of NI results where the wt probes failed to hybridize to their corresponding sequences could result from the inaccessibility of the genomic sequence in a given sample, such as when secondary DNA structures are present. This problem has been noted in rpoB hybridization in particular, and might play a role in the observed high occurrence (27.5%) of NI results proven to be RMP-susceptible in this study.
CONCLUSIONS
Although the MTBDRplus test has been proven to be a reliable, rapid and easy diagnostic for the simultaneous detection of RMP and INH resistance in M. tuberculosis, the nuances of LPA performance with regard to the occurrence and interpretation of indeterminate results are still being evaluated. This study has found the conventional interpretation of LPA-indeterminate results as resistant to be incorrect 7.5% of the time when assessing INH resistance and 27.5% of the time when assessing RMP resistance. In the case of discrepant results, we find that PSQ can be a valuable tool for rapidly evaluating LPA-indeterminate results instead of repeating phenotypic DST, LPA ¼ line-probe assay; PTB ¼pulmonary tuberculosis; EPTB ¼extra-pulmonary TB. as the technology appears to resolve discrepancies in line with phenotypic DST results.
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R E S U M E C O N T E X T E
R E S U M E N M A R C O D E R E F E R E N C I A:
Aunque los ensayos de hibridación en tiras en sondas (LPA) son prometedores, se ha hecho poca investigación para elucidar los resultados indeterminados LPA o evaluar la eficiencia de estos ensayos en una amplia gama de muestras clínicas. O B J E T I V O: Evaluar el rendimiento diagnóstico de la prueba comercial GenoType w MTBDRplus por LPA, en comparación con los resultados del enfoque clá sico de cultivo en el sistema BACTECe MGITe 960 y las pruebas de sensibilidad a los medicamentos (DST), en muestras provenientes de 308 casos de tuberculosis pulmonar (TBP) y 32 casos de TB extrapulmonar. R E S U LTA D O S: En 18 muestras de casos de TBP se obtuvo un resultado indeterminado con la prueba LPA (definidas como la ausencia de la banda de identificación de Mycobacterium tuberculosis); estas muestras se excluyeron de los siguientes aná lisis. A partir de los resultados obtenidos con las 322 muestras restantes, la prueba MTBDRplus exhibió una sensibilidad de 95,2% y una especificidad de 95,1% en el diagnóstico de la TB multidrogorresistente. En el 13,7% de las muestras de casos de TBP (40/290) la prueba LPA produjo un resultado indeterminado para isoniazida (INH), rifampicina (RMP) o ambas (definido como la ausencia de ambas bandas, es decir de la cepa natural y también las bandas correspondientes a la mutación); estas muestras se evaluaron luego por pirosecuenciación (PSQ). En contraste con la interpretación habitual de resistencia frente a un resultado indeterminado con la prueba LPA, las pruebas corrientes de DST y la PSQ confirmaron la sensibilidad a INH en el 7,5% (3/40) y a RMP en el 27,5% (11/40) de las muestras indeterminadas. C O N C L U S I O N: Cuando los resultados LPA no fueron interpretables, la PSQ resultó una técnica valiosa y rá pida para resolver la incógnita.
